This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Formula (I) a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Ar represents an indolyl group, which indolyl may optionally be substituted one or more times with substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, alkyl, hydroxy and alkoxy.
本发明涉及新型的1,4-二氮杂-双环[3.2.2]壬基
嘧啶衍
生物及其在制备药物组合物中的应用。该发明化合物被发现是
尼古丁乙酰胆碱受体的
胆碱能
配体。由于它们的药理学特性,该发明化合物可能对治疗与中枢神经系统(CNS)的
胆碱能系统、外周神经系统(
PNS)、平滑肌收缩相关的疾病或疾病、内分泌疾病或疾病、神经退行性疾病或疾病、炎症相关的疾病或疾病、疼痛以及因滥用
化学物质而引起的戒断症状等多种疾病或疾病具有用处。式(I)是其立体异构体或立体异构体的混合物,或其药学上可接受的盐,其中Ar代表
吲哚基,该
吲哚基可以选择地被卤素、三
氟甲基、三
氟甲氧基、
氰基、硝基、
氨基、烷基、羟基和烷氧基等取代基取代一次或多次。